



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES, AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: February 10, 2020

RE: PROTOCOL NRG-DT001 – Cohort A: Reopening to Accrual to Dose Level 3

Cohort A Reopening to Accrual to Dose Level 3

Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is reopened to accrual to dose level 3 effective immediately.

Cohort A will remain open to accrual until 3 wild-type p53 patients have been enrolled to dose level 3. A broadcast with more details regarding accrual closure will be sent when the target accrual has been reached.

Note: Cohort B (abdomen/pelvis/retroperitoneum) is still open to accrual to dose level 1, pending p53 results for a recently enrolled patient. If this patient has wild-type p53, enrollment will be suspended pending analysis of dose-limiting toxicities.

Please distribute this information to the appropriate personnel.

A handwritten signature in blue ink that reads "Meng Welliver".

Meng Welliver, MD, PhD